Atara Biotherapeutics (NASDAQ:ATRA) has announced plans to cut around 50% of its workforce, just a little over a week after it said the FDA had declined to approve its immunotherapy Ebvallo. The ...

Atara Biotherapeutics (ATRA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...

Atara Biotherapeutics' headquarters in Thousand Oaks. The share price of Atara Biotherapeutics Inc. began a slow climb up after the company experienced a steep drop earlier this month. The ...

Atara and its partner Pierre Fabre remain confident in the potential of EBVALLO and are committed to bringing this potential first-in-class medicine to U.S. patients with EBV+ PTLD who have ...

Rodman & Renshaw analyst Tony Buter initiated coverage of Atara Biotherapeutics (ATRA) with a Buy rating and $25 price target Atara is developing T-cell immunotherapies with a focus on the ...